Unidentified Analyst: Okay. The validation batches, are they completed, they are going through the testing, are they still need to be manufactured.
Dr. David Kideckel: We still need to have those manufactured, correct?
Unidentified Analyst: Okay. Thanks. Is that David speaking.
Dr. David Kideckel: That’s David. Yeah.
Unidentified Analyst: Okay. David, thank you. So I’ll be back in a moment. A question for Andre and the — was bought before regarding last conference call and now catalysts near-term. Could we peel that back a little bit as a catalyst regarding oral film, transdermal, VetaFilm or the CDMO?
Andre Godin: I mean there’s — like I said earlier, I think, we have a few things coming up and all of the above that you mentioned, but those are ongoing agreements that we are working on. David, is obviously involved, Dwight, everybody is involved. But it’s just taking a little bit longer than we expected, but it will happen. It’s coming, if not in the current quarter, it’s going to be in the fourth quarter for sure.
Unidentified Analyst: Okay. Will they fall into that name of significant catalysts, Andre?
Andre Godin: Yeah.
Unidentified Analyst: That was used in the last call?
Andre Godin: They’re a good catalyst. Everything is good when you announce a new partnership or your settlement or CMO contract like we just announced last week. So we’re working hard on getting these things done.
Dwight Gorham: Yeah. I think. Bigger part of that…
Unidentified Analyst: Okay.
Dwight Gorham: … rest in the human films and the VetaFilms. The CBD, I believe we’ll see major announcements on what they’ll be announcement. The big ones will be in the human side.
Unidentified Analyst: Okay. Thank you, Dwight. And I don’t know if it was covered, any new programs with the tie?
Andre Godin: Not at this time. I mean we’re working on DMP. That’s their main…
Unidentified Analyst: Yeah.
Andre Godin: … program with us, but there’s discussion, but nothing new on that front.
Unidentified Analyst: Okay. On the transdermal front, on the last call and one before there was just potential opportunities with some discussions going on with a partner for transdermal?
Dwight Gorham: Yes. I mean those conversations are ongoing. However, the focus of the organization is really making sure we bring to market reason, which is approved, and we get the proper partnership agreement with that, and then resolving epinephrine issuing getting it resubmitted to the agency. So we can get that to the market as well. Those are the two…
Unidentified Analyst: Yeah.
Dwight Gorham: …however, we do have conversations on transdermal.
Unidentified Analyst: Okay. In the resubmission for the Belbuca is, I believe in the last call, there was two items, one for Xiromed and one that was a clarification issue for IntelGenx. Is that one been resolved we believe?
Dwight Gorham: The submission to the agency is what — is next week.
Unidentified Analyst: Okay. All right. And the anticipated announcement for the CBD for animal health, is that study completed, is that still going on? I didn’t catch your comments on that, David?
Dr. David Kideckel: Yeah. So I would say right now, we have two active animal health programs, both of which I just mentioned, the one at the University of PEI. The second thing with the company. The other project that I think you’re referring to last quarter call or the quarterly call, I believe we had three ongoing projects. There was a third and the recent CBD data in dogs as reviewed by our R&D team was not as promising as we thought. There might have been a few experimental errors. We’re not exactly sure, but we decided to pull the plug on that one. So the two projects that we have right now in animal health are, again, the one in PEI, which is not material from a business standpoint, just to be very clear, that’s more going to feed into what data we can present for other potential partners down the road.
